MX367667B - Régimen de dosificación de un agonista de los receptores de s1p. - Google Patents

Régimen de dosificación de un agonista de los receptores de s1p.

Info

Publication number
MX367667B
MX367667B MX2015011590A MX2015011590A MX367667B MX 367667 B MX367667 B MX 367667B MX 2015011590 A MX2015011590 A MX 2015011590A MX 2015011590 A MX2015011590 A MX 2015011590A MX 367667 B MX367667 B MX 367667B
Authority
MX
Mexico
Prior art keywords
dosage regimen
receptor agonist
dosage
daily dosage
regimen
Prior art date
Application number
MX2015011590A
Other languages
English (en)
Inventor
Legangneux Eric
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41435196&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX367667(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX367667B publication Critical patent/MX367667B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Se administran moduladores o agonistas de los receptores de S1P siguiendo un régimen de dosificación en donde, durante los días iniciales del tratamiento, la dosificación diaria es más baja que la dosificación diaria convencional.
MX2015011590A 2008-12-22 2009-12-21 Régimen de dosificación de un agonista de los receptores de s1p. MX367667B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13967308P 2008-12-22 2008-12-22
EP09167209 2009-08-04
PCT/EP2009/067618 WO2010072703A1 (en) 2008-12-22 2009-12-21 Dosage regimen of an s1p receptor agonist

Publications (1)

Publication Number Publication Date
MX367667B true MX367667B (es) 2019-08-30

Family

ID=41435196

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2011006625A MX2011006625A (es) 2008-12-22 2009-12-21 Regimen de dosificacion de un agonista de los receptores de s1p.
MX2015011590A MX367667B (es) 2008-12-22 2009-12-21 Régimen de dosificación de un agonista de los receptores de s1p.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2011006625A MX2011006625A (es) 2008-12-22 2009-12-21 Regimen de dosificacion de un agonista de los receptores de s1p.

Country Status (34)

Country Link
US (2) US8492441B2 (es)
EP (1) EP2379069B1 (es)
JP (2) JP5657565B2 (es)
KR (1) KR101660555B1 (es)
CN (2) CN105213372A (es)
AR (1) AR074825A1 (es)
AU (1) AU2009331582B2 (es)
BR (1) BRPI0923213A2 (es)
CA (3) CA2981830A1 (es)
CY (2) CY1116321T1 (es)
DK (1) DK2379069T3 (es)
ES (1) ES2538413T3 (es)
FR (1) FR20C1022I2 (es)
HR (1) HRP20150567T1 (es)
HU (2) HUE026400T2 (es)
IL (2) IL294658A (es)
JO (1) JO3044B1 (es)
LT (1) LTC2379069I2 (es)
LU (1) LUC00160I2 (es)
MA (1) MA32907B1 (es)
MX (2) MX2011006625A (es)
NL (1) NL301046I2 (es)
NO (1) NO2020017I1 (es)
NZ (1) NZ593427A (es)
PL (1) PL2379069T3 (es)
PT (1) PT2379069E (es)
RU (1) RU2561681C2 (es)
SG (1) SG171888A1 (es)
SI (1) SI2379069T1 (es)
TN (1) TN2011000281A1 (es)
TW (1) TWI472327B (es)
UY (1) UY32350A (es)
WO (1) WO2010072703A1 (es)
ZA (1) ZA201104102B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR070842A1 (es) 2008-03-17 2010-05-05 Actelion Pharmaceuticals Ltd Regimen de dosificacion para un agonista de receptor selectivo de s1p1
SI2307007T1 (sl) * 2008-07-23 2014-11-28 Novartis Ag Modulatorji sfingozin 1 fosfatnega receptorja in njihova uporaba za zdravljenje mišičnega vnetja
PT4098256T (pt) * 2008-12-22 2025-04-10 Novartis Ag Regime de dosagem para um agonista do recetor de s1p
SG10201500639TA (en) 2010-01-27 2015-03-30 Arena Pharm Inc Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
EP2566473B1 (en) * 2010-05-06 2016-01-06 Novartis AG Dosage regimen of diaryl sulfide derivatives
EP2455080A1 (en) * 2010-11-23 2012-05-23 Almirall, S.A. S1P1 receptor agonists for use in the treatment of multiple sclerosis
UA114283C2 (uk) 2011-01-07 2017-05-25 Новартіс Аг Композиції імуносупресантів
WO2012095853A1 (en) 2011-01-10 2012-07-19 Novartis Pharma Ag Modified release formulations comprising sip receptor modulators
MX2014004813A (es) * 2011-10-21 2014-05-20 Novartis Ag Regimen de dosificacion para un modulador o agonista del receptor s1p.
HRP20200883T1 (hr) 2012-08-17 2020-09-04 Actelion Pharmaceuticals Ltd. Postupak za pripremanje (2z,5z)-5-(3-kloro-4-((r)-2,3-dihidroksipropoksi)benziliden)-2-(propilimino)-3-(o-tolil)tiazolidin-4-ona i međuproizvodi koji se koriste u navedenom postupku
EP4191245A3 (en) * 2013-04-04 2023-07-12 Novartis AG Identifying patient response to s1p receptor modulator administration
CN106456552A (zh) * 2014-04-10 2017-02-22 诺华股份有限公司 S1p调节剂的立即释放剂量方案
US20170027906A1 (en) * 2014-04-10 2017-02-02 Philippe Michel Rene Bouillot Immunosuppressant formulation
UA122064C2 (uk) 2014-12-11 2020-09-10 Актеліон Фармасьютікалз Лтд Схема дозування для селективного агоніста рецептора s1p1
MA41139A (fr) 2014-12-11 2017-10-17 Actelion Pharmaceuticals Ltd Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1
CN116850181A (zh) * 2015-01-06 2023-10-10 艾尼纳制药公司 治疗与s1p1受体有关的病症的方法
WO2016135644A1 (en) 2015-02-26 2016-09-01 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
AU2016284162A1 (en) 2015-06-22 2018-02-01 Arena Pharmaceuticals, Inc. Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(Compound1) for use in SIP1 receptor-associated disorders
CA3053416A1 (en) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations
AU2018220521A1 (en) 2017-02-16 2019-09-05 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
US11434200B2 (en) 2017-03-09 2022-09-06 Novartis Ag Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
WO2019032632A1 (en) 2017-08-09 2019-02-14 Bristol-Myers Squibb Company ALKYLPHENYL COMPOUNDS
WO2019032631A1 (en) 2017-08-09 2019-02-14 Bristol-Myers Squibb Company Oxime ether compounds
MX2020007268A (es) * 2017-09-29 2020-08-17 Novartis Ag Regimen de dosificacion de siponimod.
EP3687531A1 (en) * 2017-09-29 2020-08-05 Novartis AG Dosing regimen of siponimod
WO2019236757A1 (en) 2018-06-06 2019-12-12 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor
CA3156298A1 (en) 2019-10-31 2021-05-06 Laetitia POUZOL Combination of a cxcr7 antagonist with an s1p1 receptor modulator
WO2021158838A1 (en) 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Dosage regimen of an s1p receptor modulator
WO2021158848A1 (en) * 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Dosage regimen of an s1p receptor agonist
CN116940350A (zh) 2021-02-08 2023-10-24 博施健康爱尔兰有限公司 预防、治疗或改善溃疡性结肠炎的阿米莫德
EP4212156A1 (en) 2022-01-13 2023-07-19 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator
WO2025134072A1 (en) 2023-12-21 2025-06-26 Bausch Health Ireland Limited Methods for preventing, treating, or ameliorating ulcerative colitis in certain patient populations with amiselimod

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1176819A (zh) * 1997-09-03 1998-03-25 王树生 一种解酒饮料及其制备方法
NZ536513A (en) 2002-05-16 2007-10-26 Novartis Ag Use of EDG receptor binding agents in cancer
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
TW200505442A (en) 2003-05-19 2005-02-16 Genomics Inst Of The Novartis Res Foundation Immunosuppressant compounds and compositions
BRPI0415953B8 (pt) * 2003-10-29 2021-05-25 Wyeth Corp formulação de dosagem de liberação controlada e conjunto de formas de dosagem de liberação controlada
US20070099891A1 (en) 2003-12-17 2007-05-03 Kouichi Kino Medicinal compositions and combinations
UA74941C2 (en) 2004-04-26 2006-02-15 Fos Internat S A A metal-thermal process for producing magnesium and vacuum induction furnace for realizing the same
WO2005113330A1 (en) 2004-05-05 2005-12-01 Adler, Richard, S. Systems and methods for protecting ship from attack on the surface or under water
CN102600472A (zh) * 2004-11-29 2012-07-25 诺瓦提斯公司 S1p受体激动剂的剂量方案
CN101242856A (zh) * 2005-09-09 2008-08-13 莱博法姆公司 持续药物释放的组合物
WO2008072056A1 (en) * 2006-12-14 2008-06-19 Pfizer Limited Use of mtp inhibitors for the treatment of obesity using low doses and dose-escalation
DE102007019417A1 (de) * 2007-04-23 2008-11-13 Grünenthal GmbH Tapentadol zur Schmerzbehandlung bei Arthrose
JOP20080436B1 (ar) * 2007-10-12 2023-03-28 Novartis Ag تركيبات تشتمل على معدلات مستقبل سفينجوزين 1 فوسفات (s1p)

Also Published As

Publication number Publication date
JO3044B1 (ar) 2016-09-05
HRP20150567T1 (hr) 2015-08-14
JP2015038097A (ja) 2015-02-26
IL213347A0 (en) 2011-07-31
CA2747992C (en) 2017-11-07
CA3105857C (en) 2023-08-01
PT2379069E (pt) 2015-07-03
UY32350A (es) 2010-04-30
RU2561681C2 (ru) 2015-08-27
SG171888A1 (en) 2011-07-28
KR20110106399A (ko) 2011-09-28
US8492441B2 (en) 2013-07-23
US20110039818A1 (en) 2011-02-17
TW201028147A (en) 2010-08-01
CN102264363A (zh) 2011-11-30
BRPI0923213A2 (pt) 2016-01-26
CA2747992A1 (en) 2010-07-01
NZ593427A (en) 2013-11-29
IL294658A (en) 2022-09-01
PL2379069T3 (pl) 2015-08-31
JP2012513378A (ja) 2012-06-14
IL213347B (en) 2019-11-28
NL301046I1 (nl) 2020-06-17
AU2009331582A1 (en) 2011-06-30
CY2020014I1 (el) 2020-11-25
MX2011006625A (es) 2011-09-28
HUS2000017I1 (hu) 2020-07-28
AR074825A1 (es) 2011-02-16
ES2538413T3 (es) 2015-06-19
MA32907B1 (fr) 2011-12-01
FR20C1022I2 (fr) 2021-06-11
CA2981830A1 (en) 2010-07-01
DK2379069T3 (en) 2015-06-08
LTC2379069I2 (lt) 2022-05-25
EP2379069A1 (en) 2011-10-26
FR20C1022I1 (es) 2020-07-31
NL301046I2 (nl) 2020-07-29
HK1159524A1 (en) 2012-08-03
NO2020017I1 (no) 2020-06-17
AU2009331582B2 (en) 2014-03-13
TWI472327B (zh) 2015-02-11
TN2011000281A1 (en) 2012-12-17
JP5941110B2 (ja) 2016-06-29
LTPA2020513I1 (lt) 2020-07-27
CY1116321T1 (el) 2017-02-08
LUC00160I1 (es) 2020-06-19
CN105213372A (zh) 2016-01-06
CA3105857A1 (en) 2010-07-01
ZA201104102B (en) 2012-02-29
WO2010072703A1 (en) 2010-07-01
CY2020014I2 (el) 2020-11-25
SI2379069T1 (sl) 2015-07-31
JP5657565B2 (ja) 2015-01-21
LUC00160I2 (es) 2021-07-06
KR101660555B1 (ko) 2016-09-27
EP2379069B1 (en) 2015-03-04
US20130281712A1 (en) 2013-10-24
HUE026400T2 (en) 2016-06-28

Similar Documents

Publication Publication Date Title
MX367667B (es) Régimen de dosificación de un agonista de los receptores de s1p.
UY32352A (es) Régimen de dosificación para un agonista de los receptores de s1p
CL2011000835A1 (es) Compuestos derivados de espiro-oxindol; moduladores de los canales de sodio; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento del dolor, depresion, enfermedades cardiovasculares, respiratorias, psiquiatricas, entre otras.
EA201692167A1 (ru) Модуляторы толл-подобных рецепторов
MX2015002378A (es) Composicion ansiolitica, formulacion y metodo de uso.
CL2012000921A1 (es) Compuestos derivados de espiropiperidina-metilbenciloxifenil, activadores del receptor rpg-40; composicion farmaceutica que los comprende; y uso del compuesto para tratar diabetes.
ECSP10010106A (es) Trans-clomifeno para el síndrome metabólico
PE20142371A1 (es) Combinacion farmaceutica de 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepileptico
CO6551740A2 (es) Derivados pirazólicos como moduladores de los canales de calcio activados por la liberación de calcio
EA201000046A1 (ru) Замещенные имидазогетероциклы
CL2012001722A1 (es) Compuestos derivados de 3-hidroxi-5-arilisotiazol, agonistas del receptor 40 acoplado a la proteina g (gpr40); composición farmacéutica que los comprende; y método para el tratamiento o la prevención de la diabetes.
MX2017000627A (es) Metodos para tratar pacientes con hipercolesterolemia familiar heterocigota (hfhe).
UY30572A1 (es) N-(1-ftalazin-1-il-piperidin-4-il)-amidas como moduladores del receptor ep2
MX366197B (es) Metodo de monitoreo terapeutico de farmacos depuradores de nitrogeno.
CO6351779A2 (es) Inhibidores de molecula pequeña de la activacion n-terminal del receptor de androgenos
BR112021020234A2 (pt) Terapia de combinação que compreende compostos da fórmula (i) e agonistas de receptor de glp-1
CL2009001018A1 (es) Utilizacion de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia, teniendo los pacientes un incremento del nivel de creatinina debido a la utilizacion de dronedarona.
UY31646A1 (es) Uso de fenilimidazolidinas sustituidas para producir medicamentos para el tratamiento del síndrome metabólico
CU20130155A7 (es) Régimen de dosificación para un agonista de los receptores de s1p
UY32360A (es) Compuestos de etanamina y métodos de utilización de los mismos 545
CR11188A (es) Compuestos de bencensulfonamida apropiados para tratar trastornos que responden a la modulacion del receptor de dopamina d3
AR061139A1 (es) Tratamiento de los calores subitos con antagonistas del receptor muscarinico
AR062306A1 (es) Milnacipran para el rtamiento de disfuncion cognoscitiva asociada con fibromalgia
AR062307A1 (es) Milnacipran parel tratamiento de fatigas asociadas con el sindrome de fibromalgia
CL2009002112A1 (es) Un compuesto derivado de carbamoiloxi-arilalcanoil-arilpiperazina; composicion farmaceutica que comprende a dicho compuesto, util para el tratamiento del dolor, la ansiedad o la depresion.